PE16399A1 - Compuestos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores - Google Patents
Compuestos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptoresInfo
- Publication number
- PE16399A1 PE16399A1 PE1997001070A PE00107097A PE16399A1 PE 16399 A1 PE16399 A1 PE 16399A1 PE 1997001070 A PE1997001070 A PE 1997001070A PE 00107097 A PE00107097 A PE 00107097A PE 16399 A1 PE16399 A1 PE 16399A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- guanidinyl
- alkynyl
- formula
- alpha
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- -1 GUANIDINYL Chemical class 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 2
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 title 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 abstract 2
- 101100240517 Caenorhabditis elegans nhr-11 gene Proteins 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 abstract 1
- 206010028735 Nasal congestion Diseases 0.000 abstract 1
- 206010033078 Otitis media Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical class C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 201000009890 sinusitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: R1 ES H, ALQUILO o NO EXISTE, CUANDO EL ENLACE (a) ES UN DOBLE ENLACE; "B" ES NR9, CR3=CR8, S, ENTRE OTROS; "D" ES CR2 o SI B ES CR3, ENTONCES "D" PUEDE SER NITROGENO, EN DONDE: R2 ES H, ALQUILO C1-C3, AMINO, ENTRE OTROS; R9 ES H, ALQUILO C1-C3, ALQUENILO C1-C3, ALQUINILO C1-C3, CICLOALQUILO, CICLOALQUENILO; R3, R7 Y R8 SON H, ALQUILO C1-C3, ALQUENILO C1-C3, ALQUINILO C1-C3, CICLOALQUILO, CICLOALQUENILO, ALQUILTIO C1-C3, ALCOXI C1-C3, ENTRE OTROS; R4, R5 Y R6 SON H, ALQUILO C1-C3, ALQUENILO C1-C3, ENTRE OTROS, CON LA CONDICION DE QUE UNO DE R4, R5 Y R6 ES NH-C(=NR10)NHR11 (GUANIDINILO), EN DONDE: R10 Y R11 ES H, METILO Y ETILO; SIENDO UN COMPUESTO (I) PREFERIDO: (4-METILBENCIMIDAZOL-5-IL)GUANIDINA. TAMBIEN SE REFIERE A LA COMPOSICION QUE COMPRENDE UN COMPUESTO DE FORMULA (I) Y UNO O MAS PRINCIPIOS ACTIVOS COMO UN ANTIHISTAMINICO, ANTIINFLAMATORIO, ENTRE OTROS. LOS COMPUESTOS DE FORMULA (I) ACTUAN COMO AGONISTA DE ALFA 2 ADRENORECEPTORES, SIENDO UTILES EN EL TRATAMIENTO DE CONGESTION NASAL, OTITIS MEDIA, SINUSITIS, ASMA, DOLOR, MIGRANA, ABUSO DE SUSTANCIA Y ADICCION, TRASTORNO GASTROINTESTINAL, ULCERA, HIPERACIDEZ ESTOMACAL, HIPERTROFIA PROSTATICA BENIGNA, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3202396P | 1996-11-25 | 1996-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE16399A1 true PE16399A1 (es) | 1999-03-12 |
Family
ID=21862692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1997001070A PE16399A1 (es) | 1996-11-25 | 1997-11-25 | Compuestos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US6225331B1 (es) |
| EP (1) | EP0944604B1 (es) |
| JP (1) | JP2001506600A (es) |
| KR (1) | KR20000069131A (es) |
| CN (1) | CN1104422C (es) |
| AR (1) | AR009145A1 (es) |
| AT (1) | ATE286885T1 (es) |
| AU (1) | AU730369B2 (es) |
| BR (1) | BR9713536A (es) |
| CA (1) | CA2272640C (es) |
| CO (1) | CO4910148A1 (es) |
| CZ (1) | CZ184099A3 (es) |
| DE (1) | DE69732244T2 (es) |
| ES (1) | ES2236833T3 (es) |
| HU (1) | HUP0000312A3 (es) |
| ID (1) | ID23857A (es) |
| IL (1) | IL130077A0 (es) |
| NO (1) | NO313912B1 (es) |
| NZ (1) | NZ336010A (es) |
| PE (1) | PE16399A1 (es) |
| RU (1) | RU2194700C2 (es) |
| SK (1) | SK69799A3 (es) |
| TR (1) | TR199901468T2 (es) |
| WO (1) | WO1998023596A1 (es) |
| ZA (1) | ZA9710578B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000069131A (ko) | 1996-11-25 | 2000-11-25 | 데이비드 엠 모이어 | 알파-2 아드레날린수용체 아고니스트로서 유용한 구아니디닐 헤테로사이클 화합물 |
| US6291514B1 (en) * | 1998-02-09 | 2001-09-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors |
| DZ3415A1 (fr) * | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
| BR0113747A (pt) * | 2000-09-08 | 2003-06-24 | Warner Lambert Co | Prevenção de sinusite aguda e ataque sinusal |
| WO2002081443A1 (en) * | 2001-04-09 | 2002-10-17 | Chiron Corporation | Novel guanidino compounds |
| US20030195187A1 (en) * | 2002-02-04 | 2003-10-16 | Chiron Corporation | Guanidino compounds |
| US20030207814A1 (en) * | 2002-02-04 | 2003-11-06 | Chiron Corporation | Novel guanidinyl derivatives |
| US20050124652A1 (en) * | 2002-02-04 | 2005-06-09 | Rustum Boyce | Guanidino compounds |
| WO2003072056A2 (en) * | 2002-02-25 | 2003-09-04 | Chiron Corporation | Intranasal administration of mc4-r agonists |
| MXPA04011557A (es) * | 2002-05-23 | 2005-07-05 | Chiron Corp | Compuestos de quinazolinona sustituida. |
| EP1651229A1 (en) * | 2003-05-23 | 2006-05-03 | Chiron Corporation | Guanidino-substituted quinazolinone compounds as mc4-r agonists |
| RU2254855C2 (ru) * | 2003-09-10 | 2005-06-27 | Открытое акционерное общество "Акционерное курганское общество медицинских препаратов и изделий "Синтез" | Противовирусное средство и способ его получения |
| EP1686996A4 (en) * | 2003-11-19 | 2008-11-12 | Novartis Vaccines & Diagnostic | CHINAZOLINONE COMPOUNDS WITH REDUCED BIOAC CUMULATION |
| EP1883451B9 (en) * | 2005-04-13 | 2011-02-09 | Neuraxon Inc. | Substituted indole compounds having nos inhibitory activity |
| KR20080065704A (ko) | 2005-11-09 | 2008-07-14 | 콤비네이토릭스, 인코포레이티드 | 의학적 이상의 치료 방법들, 조성물들, 및 키트들 |
| TWI417099B (zh) * | 2007-03-23 | 2013-12-01 | Neuraxon Inc | 具抑制一氧化氮合成酶活性之喹諾酮、四氫喹啉及其相關化合物 |
| CA2705833A1 (en) * | 2007-11-16 | 2009-05-22 | Subhash C. Annedi | 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity |
| US20100196286A1 (en) * | 2008-12-01 | 2010-08-05 | Armer Thomas A | Inhalation delivery methods and devices |
| US8555875B2 (en) | 2008-12-23 | 2013-10-15 | Map Pharmaceuticals, Inc. | Inhalation devices and related methods for administration of sedative hypnotic compounds |
| GB0919889D0 (en) * | 2009-11-13 | 2009-12-30 | Biocopea Ltd | Drug composition and its use in therapy |
| WO2012101013A1 (en) * | 2011-01-28 | 2012-08-02 | Boehringer Ingelheim International Gmbh | Substituted pyridinyl-pyrimidines and their use as medicaments |
| CN112047947A (zh) * | 2020-10-13 | 2020-12-08 | 石药集团新诺威制药股份有限公司 | 一种茶碱的合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU148414A1 (ru) * | 1961-07-03 | 1961-11-30 | Е.Н. Зильберман | Способ получени имидазолов и оксазолов |
| US3908013A (en) | 1970-09-17 | 1975-09-23 | Armour Pharma | Pharmaceutical aromatic guanidine compositions and methods of using same |
| BE795970A (fr) | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
| US3947455A (en) | 1974-04-15 | 1976-03-30 | Armour Pharmaceutical Company | 5'-(8'-Hydroxyquinolyl)guanidine compounds |
| US4000279A (en) | 1974-10-29 | 1976-12-28 | Armour Pharmaceutical Company | Pharmaceutical preparations containing 5'-(8'-hydroxyquinolyl)guanidine compounds and methods of using same |
| KR860002082A (ko) * | 1984-08-29 | 1986-03-26 | 프랑시스 글로리 | 자기 변환기 헤드 구조물 |
| NZ221729A (en) * | 1986-09-15 | 1989-07-27 | Janssen Pharmaceutica Nv | Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions |
| US5091528A (en) | 1990-09-12 | 1992-02-25 | Allergan, Inc. | 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents |
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| WO1995016449A1 (en) * | 1993-12-17 | 1995-06-22 | The Procter & Gamble Company | 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists |
| KR20000069131A (ko) | 1996-11-25 | 2000-11-25 | 데이비드 엠 모이어 | 알파-2 아드레날린수용체 아고니스트로서 유용한 구아니디닐 헤테로사이클 화합물 |
| US6057329A (en) * | 1996-12-23 | 2000-05-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives |
-
1997
- 1997-11-21 KR KR1019997004619A patent/KR20000069131A/ko not_active Ceased
- 1997-11-21 ID IDW990410A patent/ID23857A/id unknown
- 1997-11-21 TR TR1999/01468T patent/TR199901468T2/xx unknown
- 1997-11-21 IL IL13007797A patent/IL130077A0/xx unknown
- 1997-11-21 WO PCT/US1997/020802 patent/WO1998023596A1/en not_active Ceased
- 1997-11-21 CA CA002272640A patent/CA2272640C/en not_active Expired - Fee Related
- 1997-11-21 CN CN97181078A patent/CN1104422C/zh not_active Expired - Fee Related
- 1997-11-21 EP EP97948290A patent/EP0944604B1/en not_active Expired - Lifetime
- 1997-11-21 AT AT97948290T patent/ATE286885T1/de not_active IP Right Cessation
- 1997-11-21 HU HU0000312A patent/HUP0000312A3/hu unknown
- 1997-11-21 AU AU54381/98A patent/AU730369B2/en not_active Ceased
- 1997-11-21 US US09/308,788 patent/US6225331B1/en not_active Expired - Lifetime
- 1997-11-21 CZ CZ991840A patent/CZ184099A3/cs unknown
- 1997-11-21 RU RU99113446/04A patent/RU2194700C2/ru not_active IP Right Cessation
- 1997-11-21 DE DE69732244T patent/DE69732244T2/de not_active Expired - Lifetime
- 1997-11-21 SK SK697-99A patent/SK69799A3/sk unknown
- 1997-11-21 JP JP52469498A patent/JP2001506600A/ja active Pending
- 1997-11-21 ES ES97948290T patent/ES2236833T3/es not_active Expired - Lifetime
- 1997-11-21 NZ NZ336010A patent/NZ336010A/en unknown
- 1997-11-21 BR BR9713536-4A patent/BR9713536A/pt not_active IP Right Cessation
- 1997-11-24 CO CO97068606A patent/CO4910148A1/es unknown
- 1997-11-25 ZA ZA9710578A patent/ZA9710578B/xx unknown
- 1997-11-25 PE PE1997001070A patent/PE16399A1/es not_active Application Discontinuation
- 1997-11-25 AR ARP970105530A patent/AR009145A1/es unknown
-
1999
- 1999-05-25 NO NO19992498A patent/NO313912B1/no unknown
-
2000
- 2000-12-01 US US09/727,900 patent/US6391878B2/en not_active Expired - Lifetime
-
2002
- 2002-02-08 US US10/071,284 patent/US20020128481A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE16399A1 (es) | Compuestos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores | |
| PE16299A1 (es) | Compuestos de 2-imidazolinilaminoindol utiles como agonistas de alfa-2 adrenoreceptores | |
| PE106499A1 (es) | Antagonistas del receptor ccr-3 | |
| DE60230127D1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
| DK0687251T3 (da) | 1,3-dihydroindol-2-on-derivater, der er substitueret i 3-stillingen med en nitrogengruppe, til anvendelse som vasopressin- og/eller ocytocin-agonister og/eller -antagonister | |
| PE20040526A1 (es) | Amidas de 4-alquenil piperidina de indol, azaindol y relacionadas con heterociclicos | |
| PE20091093A1 (es) | Compuesto heterociclico que contiene nitrogeno y su uso | |
| PE20081557A1 (es) | Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos | |
| SE8500368D0 (sv) | Heterocykliska foreningar | |
| TR200103335T2 (tr) | Proteaz inhibitörleri olarak amin türevleri | |
| AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
| DE3850203D1 (de) | Benzimidazolin-2-oxo-1-carboxylsäure-Derivate, verwendbar als Antagonisten von 5-HT-Rezeptoren. | |
| AR247213A1 (es) | Preparacion de acido 7-¡(1-carboxi-3-fenilpropil)amino¿-3,4,6,7,8,12b-octahidro-6-oxopirido ¡2,1-a¿ o hexahidro-6-oxo-1h(1,4-tiazino¡3,4-a¿¡2¿-benzazepin-4-carboxilico, agentes hipertensivos. | |
| ES2172580T3 (es) | 1,3-oxatiolanos sustituidos con propiedades antiviricas. | |
| PE20050460A1 (es) | COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO) | |
| DE59914814D1 (de) | Heterozyklische substituierte amide, deren herstellung und anwendung | |
| PE20051054A1 (es) | Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento | |
| BR0000654A (pt) | Preparação de composição de borracha vulcanizada com peróxido e artigos tendo ela pelo menos como um dos seus componentes | |
| PE20001084A1 (es) | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas | |
| PE83999A1 (es) | Azetidinas | |
| CO5271666A1 (es) | Derivados de pirimidina | |
| PE29798A1 (es) | Acetidinas | |
| ES2180932T3 (es) | Derivados de camptotecina y su uso como agentes antitumorales. | |
| PE16599A1 (es) | Compuestos de (2-imidazolinilamino) benzoxazol utiles como agonistas de alfa-2 adrenoreceptores | |
| IT1271411B (it) | Derivati del 2-ammino-1,2,3,4-tetraidro-naftalene attivi sul sistema cardiovascolare |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |